Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Lacy

Showing results (21-30 of 59) with videos related to

Pageof 6
Sort By:
Oncotarget|September 11, 2018
Genomic mutations and histopathologic biomarkers in YMeaghan S Dendy, Johannes M Ludwig, Nima Kokabi, et al.
Journal of Gastrointestinal Oncology|January 4, 2019
Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancerBrandon R Mancini, Stacey Stein, Shane Lloyd, et al.
Pancreas|July 14, 2020
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic CancerMichael Cecchini, Joseph A Miccio, Jay Pahade, et al.
American Journal of Clinical Oncology|August 22, 2014
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal AdenocarcinomaJia Li, Xiaopan Yao, Jeremy S Kortmansky, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
EBNA1 regulates cellular gene expression by binding cellular promotersAllon Canaan, Izhak Haviv, Alexander E Urban, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancerBarbara Burtness, Laurie Thomas, Rebecca Sipples, et al.
Journal of Gastrointestinal Oncology|July 11, 2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancerNipun Verma, Kimberly L Johung, Jeremy Kortmansky, et al.
The Oncologist|October 14, 2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutationsFaiza Yasin, Ethan Sokol, Neil Vasan, et al.
Journal of Gastrointestinal Oncology|July 12, 2023
Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancerGabrielle W Peters, Wesley Talcott, Nicholas V Peters, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC ProfilingDejiang Wang, Xiangjun Di, Fu Gao, et al.
Pageof 6

Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Oncotarget|September 11, 2018
Genomic mutations and histopathologic biomarkers in YMeaghan S Dendy, Johannes M Ludwig, Nima Kokabi, et al.
Journal of Gastrointestinal Oncology|January 4, 2019
Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancerBrandon R Mancini, Stacey Stein, Shane Lloyd, et al.
Pancreas|July 14, 2020
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic CancerMichael Cecchini, Joseph A Miccio, Jay Pahade, et al.
American Journal of Clinical Oncology|August 22, 2014
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal AdenocarcinomaJia Li, Xiaopan Yao, Jeremy S Kortmansky, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 19, 2010
EBNA1 regulates cellular gene expression by binding cellular promotersAllon Canaan, Izhak Haviv, Alexander E Urban, et al.
Cancer Journal (Sudbury, Mass.)|September 1, 2007
Phase II trial of weekly docetaxel/irinotecan combination in advanced pancreatic cancerBarbara Burtness, Laurie Thomas, Rebecca Sipples, et al.
Journal of Gastrointestinal Oncology|July 11, 2024
A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancerNipun Verma, Kimberly L Johung, Jeremy Kortmansky, et al.
The Oncologist|October 14, 2024
Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutationsFaiza Yasin, Ethan Sokol, Neil Vasan, et al.
Journal of Gastrointestinal Oncology|July 12, 2023
Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancerGabrielle W Peters, Wesley Talcott, Nicholas V Peters, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Epigenomic Heterogeneity of Non-Functional Pancreatic Neuroendocrine Tumors Uncovered by Single nucleus and Spatial ATAC ProfilingDejiang Wang, Xiangjun Di, Fu Gao, et al.
Pageof 6